Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets.

Details

Ressource 1Download: 22510872_Postprint.pdf (12840.51 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_E4B1C2D974C9
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets.
Journal
Blood
Author(s)
Travert M., Huang Y., de Leval L., Martin-Garcia N., Delfau-Larue M.H., Berger F., Bosq J., Brière J., Soulier J., Macintyre E., Marafioti T., de Reyniès A., Gaulard P.
ISSN
1528-0020 (Electronic)
ISSN-L
0006-4971
Publication state
Published
Issued date
2012
Volume
119
Number
24
Pages
5795-5806
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Abstract
The pathogenesis of hepatosplenic T-cell lymphoma (HSTL), a rare entity mostly derived from γδ T cells and usually with a fatal outcome, remains largely unknown. In this study, HSTL samples (7γδ and 2αβ) and the DERL2 HSTL cell line were subjected to combined gene-expression profiling and array-based comparative genomic hybridization. Compared with other T-cell lymphomas, HSTL had a distinct molecular signature irrespective of TCR cell lineage. Compared with peripheral T-cell lymphoma, not otherwise specified and normal γδ T cells, HSTL overexpressed genes encoding NK-cell-associated molecules, oncogenes (FOS and VAV3), the sphingosine-1-phosphatase receptor 5 involved in cell trafficking, and the tyrosine kinase SYK, whereas the tumor-suppressor gene AIM1 (absent in melanoma 1) was among the most down-expressed. We found highly methylated CpG islands of AIM1 in DERL2 cells, and decitabine treatment induced a significant increase in AIM1 transcripts. Syk was present in HSTL cells and DERL2 cells contained phosphorylated Syk and were sensitive to a Syk inhibitor in vitro. Genomic profiles confirmed recurrent isochromosome 7q (n = 6/9) without alterations at the SYK and AIM1 loci. Our results identify a distinct molecular signature for HSTL and highlight oncogenic pathways that offer rationale for exploring new therapeutic options such as Syk inhibitors and demethylating agents.
Keywords
Adult, Aged, Base Sequence, Cell Lineage/genetics, Chromosome Aberrations, Cluster Analysis, Crystallins/metabolism, Drug Resistance, Neoplasm/genetics, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Genes, Neoplasm/genetics, Humans, Intracellular Signaling Peptides and Proteins/antagonists & inhibitors, Intracellular Signaling Peptides and Proteins/metabolism, Isochromosomes/genetics, Liver Neoplasms/drug therapy, Liver Neoplasms/genetics, Lymphoma, T-Cell/drug therapy, Lymphoma, T-Cell/genetics, Male, Membrane Proteins/metabolism, Middle Aged, Molecular Sequence Data, Molecular Targeted Therapy, Protein-Tyrosine Kinases/antagonists & inhibitors, Protein-Tyrosine Kinases/metabolism, Receptors, Antigen, T-Cell, alpha-beta/genetics, Receptors, Antigen, T-Cell, gamma-delta/genetics, Splenic Neoplasms/drug therapy, Splenic Neoplasms/genetics, Tumor Markers, Biological/genetics, Tumor Markers, Biological/metabolism, Young Adult
Pubmed
Web of science
Open Access
Yes
Create date
17/09/2012 15:38
Last modification date
20/08/2019 17:08
Usage data